Recent Updates
Recently added Catalysts
IMRX Positive Sentiment

Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors

Thursday, October 12, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: IMM-1-104 exhibits promising anti-tumor activity across 20 tumor types, particularly in RAS or RAF mutant tumors. The drug shows high sensitivity in melanoma, pancreatic, and lung cancers. Additionally, it enhances the effectiveness of gemcitabine and paclitaxel in pancreatic cancer models and outperforms binimetinib in combination with encorafenib in terms of tumor growth inhibition.
Price reaction · baseline $6.3199 (2023-10-12T15:59:00.000Z) · hit during market hours · 1 other IMRX headline(s) in the window, move may be shared
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • IMM-1-104 shows significant anti-tumor activity across various tumor types.
  • The drug demonstrates enhanced effectiveness in combination therapies.
  • Pharmacogenomic data helps identify responsive patient subpopulations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor

Full Press Release Details

• Anti-tumor activity of IMM-1-104 was characterized in 193 tumor models spanning 20 distinct tumor types in the humanized 3D-tumor growth assay (3D-TGA) using cancer-specific, patient-aligned cell lines.
• IMM-1-104 demonstrated diverse responses across a wide range of MAPK-driven tumor types, including those with RAS or RAF mutations.
• Pharmacogenomic data were used to generate a model predictive of response to IMM-1-104 and identify biomarker-aligned patient subpopulations.
• Sensitivity to IMM-1-104 (IC50 < 1uM) tested in 3D-TGA cell lines was highest in melanoma (62.5%) followed by pancreatic cancer (35.0%) and lung cancer (16.7%).
• IMM-1-104 was tested in combination with gemcitabine or paclitaxel in humanized 3D models of pancreatic cancer, demonstrating enhanced activity and combination therapy potential.
• IMM-1-104 in combination with encorafenib drove deeper regressions and superior durability of response in a head-to-head in vivo comparison versus binimetinib plus encorafenib. Tumor growth inhibition (TGI) was between 89.8% and 95.2% with the IMM-1-104 plus encorafenib combination and 73.7% with the binimetinib plus encorafenib combination.

Frequently Asked Questions

What types of tumors did IMM-1-104 target?

IMM-1-104 was tested on 20 distinct tumor types, showing activity in RAS and RAF mutant tumors.

How effective is IMM-1-104 in melanoma?

IMM-1-104 demonstrated a sensitivity of 62.5% in melanoma models.

What combination therapies were tested with IMM-1-104?

IMM-1-104 was tested in combination with gemcitabine, paclitaxel, and encorafenib.

What was the tumor growth inhibition rate with encorafenib?

The combination of IMM-1-104 and encorafenib achieved tumor growth inhibition rates between 89.8% and 95.2%.

ShareAdd on Google
Tags: IMRX Viatris Investor Conferences Healthcare IMM-1-104 RAS mutant tumors RAF mutant tumors pancreatic cancer melanoma
Last updated: Oct 12, 2023

Biotech snapshot

Cash runway
$202M liquidity · $6M/mo burn
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 MonotherapyPhase 1
Advanced Solid Tumor →

Catalyst track record

+41%
best trade around IMRX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for IMRX.

See every catalyst's timing & PoA →